Oracle Is Down 48%: AI Backlog Bargain or Debt-Fueled Trap?

Oracle's 48% drop is old damage; the current debate is about financing

Oracle's 13% decline this year matters more than the headline drawdown. Despite a Q4 beat on earnings and revenue, investors are still selling because the bigger issue is how Oracle is funding its AI expansion. After last week's selloff, the market is treating debt and cash timing as the core risk, not weak demand.

That split becomes clearer in the peer comparison. Oracle fell 24.8% in the first half of 2026, while Amazon and Alphabet stayed positive. Bulls point to Oracle's huge AI backlog as evidence that demand is real. Bears focus on $130 billion in debt, roughly $24 billion in negative free cash flow, and management's plan to raise another $40 billion. For now, the stock is being judged less on demand visibility than on whether the balance sheet can support it.

Oracle's AI backlog is large, but concentration still matters

Why bulls see committed demand

Oracle's order backlog stands at $638 billion. Management describes that figure as contracts that are signed but not yet delivered, and the company says it is larger than comparable figures reported by Microsoft, Amazon, and Google. In the December quarter, that visibility was also reflected in Remaining Performance Obligations of $523 billion, while cloud revenue grew 34%.

That does not make Oracle a safe AI play. It does mean the bull case rests on more than speculation: customers have already committed to capacity, and cloud growth shows the business is still expanding. The catch is concentration. The same order backlog stands at $638 billion includes the warning that more than 50% of Oracle's backlog is tied to OpenAI, so execution and customer concentration remain central to the story.

Cash flow is the real issue keeping Oracle under pressure

After the recent 13% decline this year, another earnings beat was not enough to lift the stock. The market is focused on a harder question: whether Oracle's backlog can be funded and converted without constantly increasing financial strain.

Why investors are fixated on funding

Oracle reported $23.7 billion in negative free cash flow for the fiscal year and said it plans to raise $40 billion through debt and equity, including a $20 billion share sale. That is why the debate has shifted from demand to durability. A backlog can show demand, but free cash flow determines whether that demand can support capex and debt without more financing.

The bear case is straightforward. Oracle is accelerating spending faster than investors see cash conversion. As a result, the market is pricing dilution, leverage, and execution risk rather than rewarding backlog growth alone.

What the market needs to see

The key test is not whether backlog grows again. It is whether Oracle can show that revenue conversion and customer prepayments are improving the cash story. Management has pointed to $20 billion to $25 billion in customer prepayments against fiscal 2027 capex, but the market wants clearer proof that financing needs are becoming more manageable, not less.

Is Oracle a buy now, or still too early?

Oracle only becomes a stronger buy if the next few quarters show backlog turning into revenue and cash flow in a way that calms funding fears. The market is still reacting to the fact that Oracle reported another $20 billion capital raise and forecast fiscal 2027 spending above Wall Street estimates.

What would improve the case

• Backlog converts into revenue faster than expected.
• Free cash flow improves from the recently reported $23.7 billion in negative free cash flow.
• Financing activity stops dominating the story.

What would keep the bear case intact

• Spending keeps rising faster than cash conversion.
• Dilution or debt levels stay elevated.
• OpenAI concentration remains the main reason the backlog looks impressive.

Right now, Oracle looks less like a simple value trade and more like a proof point waiting to happen. The AI demand story is plausible. The financing story is still doing the heavy lifting in the stock price.